EZH2 and mesothelioma: The results of the survival analysis showed that the survival time was 26.3 (23–32.7) months in low expression group, while 13.7 (9.9–17.9) months in high expression group was, indicating that the EZH2 expression acted as an independent prognostic factor for the survival of mesothelioma patients (HR = 2.63, 95% CI 1.02–6.79, P = 0.046) (Fig. 1B).